Milrinon Tillomed (Milrinone)

• Milrinone acts as a phosphodiesterase‑3 inhibitor to support cardiac function in critical heart conditions.
• Acute decompensated heart failure: enhances myocardial contractility and lowers pulmonary congestion.
• Cardiogenic shock: provides inotropic and vasodilatory support to maintain systemic perfusion.
• Low cardiac output syndrome after cardiac surgery: improves cardiac output when conventional therapy is insufficient.

• Milrinone selectively inhibits the phosphodiesterase‑3 enzyme in cardiac and vascular smooth muscle cells, leading to an accumulation of cyclic adenosine monophosphate (cAMP). Elevated cAMP increases calcium influx in myocardial cells, producing a positive inotropic effect, while simultaneously causing relaxation of vascular smooth muscle, resulting in vasodilation and reduced afterload.

Milrinone may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Hypotension: drop in blood pressure after infusion.
• Headache: mild to moderate intensity.
• Arrhythmias: premature ventricular contractions or tachycardia.
• Nausea: occasional gastrointestinal upset.
• Flushing: transient warmth and redness of skin.
• Tachycardia: increased heart rate.

Serious or Rare Side Effects

• Severe hypotension: profound blood pressure fall requiring intervention.
• Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
• Myocardial ischemia: reduced blood flow to heart muscle.
• Thrombocytopenia: low platelet count.
• Anaphylactic reactions: rare allergic responses.
• Cardiac arrest: sudden loss of heart function.

• Milrinone requires careful monitoring and specific safety measures before and during therapy.
• Cardiac monitoring: continuous ECG and hemodynamic assessment are recommended.
• Electrolyte balance: correct potassium and magnesium levels to reduce arrhythmia risk.
• Renal impairment: adjust dosing in patients with reduced kidney function.
• Concomitant vasodilators: use cautiously to avoid excessive hypotension.
• Pregnancy and lactation: safety not established; weigh benefits against potential risks.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

• Other phosphodiesterase inhibitors: may cause profound hypotension.
• Strong vasodilators (e.g., nitroprusside): increase risk of severe blood pressure drop.
• Concurrent inotropes: additive effect on cardiac rhythm leading to arrhythmias.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt desired inotropic response.
• Diuretics: can exacerbate electrolyte disturbances.
• Anticoagulants: monitor for bleeding if thrombocytopenia occurs.
• CYP3A4 inhibitors/inducers: may alter milrinone plasma levels.